Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II trial of an inactivated bivalent enterovirus vaccine in healthy adults, children, and infants/young children
CTR20232961Phase 2Active
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of bivalent enterovirus vaccine (CA16/EV71), inactivated in herpangina, enteroviral infection, sponsored by Sinovac Biotech Ltd.. Started Sep 2023; status: active.
02
Drugs
bivalent enterovirus vaccine (CA16/EV71), inactivated
03
Conditions
herpanginaenteroviral infection
Beyond the preview
Go deeper on CTR20232961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232961.